drugset
drugset / Trial / NCT00618293

Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis

NCT00618293 ↗

Phase 2 Withdrawn Heinrich-Heine University, Duesseldorf CSL Behring · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluation of efficacy by determination of transfusion requirements and safety by determination of adverse events in administration of Von Willebrand factor concentrate F VIII (Haemate).

Timeline

Start
2008-01
Primary completion
2010-07
Completion
2011-07

Outcome

Outcome not reported

Stopped: “No patient met the criteria for inclusion in the study.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haemate HS Protein / enzyme biologic — Intravenous

Indications

No indication recorded.